Table 1.
Agents in clinical development that target the insulin-like growth factor pathway
| Company | Compound | Mechanism of Action | Phase of Clinical Development | Dosing | Types of Cancers Tested |
|---|---|---|---|---|---|
| MedImmune | MDI-573 [89] | Fully human monoclonal antibody of IGF-1 and IGF-2 | I | IV every 3 weeks | Solid tumors |
| Merck | MK-0646 [90] | Monoclonal antibody of IGF-1R | II | IV weekly, 3 weeks on, 1 week off | Non-small cell lung cancer, small cell lung cancer, prostate, breast, pancreas |
| Imclone | IMC-A12 [91,99] | Fully human Monoclonal antibody of IGF-1R | II | IV every 1 or 2 weeks | HCC, Colorectal, pancreas, mesothelioma, thymoma, prostate, head and neck |
| Biogen-Idec | BIIB 022 [92] | Monoclonal antibody of IGF-1R | I/II | IV every 2 weeks | HCC, non-small cell lung cancer |
| Sanofi-Aventis | AVE 1642 [98] | Humanized antibody of IGF-1R | I | IV every 3 weeks | HCC, multiple myeloma |
| Roche | R1507 [118] | Fully human IgG1 recombinant antibody of IGF-1R | I | Every 1 or 3 weeks | Solid tumors and Lymphoma |
| Amgen | AMG 479 [119] | Fully human Monoclonal antibody of IGF-1R | II/III | IV every 2 weeks | Pancreas, colorectal, Ewing's sarcoma, ovarian |
| Pfizer | CP-751871 [93] | Fully human Monoclonal antibody of IGF-1R | II/III | IV every 3 weeks | Non-small cell lung cancer |
| OSI | OSI-906 [100] | Small molecule inhibitor of IGF-1R | II/III | Oral twice a day | Adenocortical carcinoma, Ovarian |
| Novartis | AEW54, ADW742 [120,121] | Small molecule inhibitor of IGF-1R | preclinical | NA | NA |
| BMS | BMS-554417 [102] | Small molecule inhibitor of IGF-1R | preclinical | NA | NA |